Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Ligand Pharmaceuticals (NASDAQ:LGND) Share Price

News headlines about Ligand Pharmaceuticals (NASDAQ:LGND) have been trending somewhat positive on Saturday, Accern Sentiment reports. The research group rates the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Ligand Pharmaceuticals earned a daily sentiment score of 0.15 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 45.8437359526388 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Ligand Pharmaceuticals (NASDAQ LGND) traded down $2.74 during mid-day trading on Friday, reaching $157.07. 223,646 shares of the company traded hands, compared to its average volume of 275,404. The company has a quick ratio of 0.95, a current ratio of 0.97 and a debt-to-equity ratio of 0.05. Ligand Pharmaceuticals has a 1 year low of $95.08 and a 1 year high of $170.30. The company has a market cap of $3,260.00, a PE ratio of 227.64, a PEG ratio of 1.71 and a beta of 1.07.

Ligand Pharmaceuticals (NASDAQ:LGND) last issued its earnings results on Thursday, November 9th. The biotechnology company reported $0.69 EPS for the quarter, beating the consensus estimate of $0.37 by $0.32. The company had revenue of $33.38 million during the quarter, compared to analysts’ expectations of $31.04 million. Ligand Pharmaceuticals had a net margin of 12.76% and a return on equity of 7.83%. The business’s revenue for the quarter was up 54.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.62 EPS. equities research analysts anticipate that Ligand Pharmaceuticals will post 3.15 earnings per share for the current year.

LGND has been the topic of a number of recent research reports. HC Wainwright reaffirmed a “buy” rating and set a $170.00 price objective on shares of Ligand Pharmaceuticals in a report on Friday. Zacks Investment Research downgraded Ligand Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 10th. Finally, Roth Capital set a $158.00 target price on Ligand Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, November 13th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. Ligand Pharmaceuticals has an average rating of “Buy” and an average target price of $150.83.

In related news, CEO John L. Higgins sold 5,269 shares of the company’s stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $142.53, for a total value of $750,990.57. Following the completion of the transaction, the chief executive officer now directly owns 143,542 shares of the company’s stock, valued at approximately $20,459,041.26. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Matthew E. Korenberg sold 6,559 shares of the company’s stock in a transaction on Friday, November 17th. The stock was sold at an average price of $142.63, for a total transaction of $935,510.17. Following the completion of the transaction, the vice president now directly owns 8,147 shares of the company’s stock, valued at $1,162,006.61. The disclosure for this sale can be found here. Insiders have sold a total of 70,852 shares of company stock valued at $10,915,823 in the last quarter. Corporate insiders own 8.30% of the company’s stock.

WARNING: This piece was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/03/ligand-pharmaceuticals-lgnd-getting-somewhat-positive-media-coverage-analysis-shows.html.

Ligand Pharmaceuticals Company Profile

Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals.

Insider Buying and Selling by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)

Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply